
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Open Neurol J</journal-id><journal-id journal-id-type="iso-abbrev">Open Neurol J</journal-id><journal-id journal-id-type="publisher-id">TONEUJ</journal-id><journal-title-group><journal-title>The Open Neurology Journal</journal-title></journal-title-group><issn pub-type="epub">1874-205X</issn><publisher><publisher-name>Bentham Open</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">3322431</article-id><article-id pub-id-type="publisher-id">TONEUJ-6-1</article-id><article-id pub-id-type="doi">10.2174/1874205X01206010001</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>Genetic Screening of the Mitochondrial Rho GTPases MIRO1 and MIRO2 in Parkinson’s Disease </plain></SENT>
</text></SecTag></article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Anvret</surname><given-names>Anna</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ran</surname><given-names>Caroline</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Westerlund</surname><given-names>Marie</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Sydow</surname><given-names>Olof</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Willows</surname><given-names>Thomas</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Olson</surname><given-names>Lars</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Galter</surname><given-names>Dagmar</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Belin</surname><given-names>Andrea Carmine</given-names></name><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="aff" rid="aff1">1</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden</aff><aff id="aff2"><label>2</label>Present address: Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden</aff><aff id="aff3"><label>3</label>Department of Neurology, Karolinska University Hospital, Stockholm, Sweden</aff><author-notes><corresp id="cor1"><label>*</label>Address correspondence to this author at the Department of Neuroscience, Karolinska Institutet, 171 77 Stockholm, Sweden; Tel: +46-8-524 870 51; Fax: +46-8-323 742; E-mail: <email xlink:href="andrea.carmine.belin@ki.se">andrea.carmine.belin@ki.se</email></corresp></author-notes><pub-date pub-type="epub"><day>3</day><month>4</month><year>2012</year></pub-date><pub-date pub-type="collection"><year>2012</year></pub-date><volume>6</volume><fpage>1</fpage><lpage>5</lpage><history><date date-type="received"><day>13</day><month>12</month><year>2011</year></date><date date-type="rev-recd"><day>20</day><month>2</month><year>2012</year></date><date date-type="accepted"><day>20</day><month>2</month><year>2012</year></date></history><permissions><copyright-statement>© Anvret <italic>et al</italic>; Licensee <italic>Bentham Open.</italic></copyright-statement><copyright-year>2012</copyright-year><copyright-holder>Anvret</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/"><license-p>This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (<uri xlink:type="simple" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</uri>) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.</license-p></license></permissions><abstract><p><SecTag type="ABS"><text><SENT sid="1" pm="."><plain>MIRO1 and MIRO2 (mitochondrial Ras homolog gene family, member T1 and T2) also referred to as RHOT1 and RHOT2, belong to the mitochondrial Rho GTPase family and are involved in axonal transport of mitochondria in neurons. </plain></SENT>
<SENT sid="2" pm="."><plain>Because mitochondrial dysfunction is strongly implicated in Parkinson’s disease (PD), MIRO1 and MIRO2 can be considered as new candidate genes for PD. </plain></SENT>
<SENT sid="3" pm="."><plain>We analyzed two non-synonymous polymorphisms and one synonymous polymorphism in MIRO1 and two non-synonymous polymorphisms in MIRO2, in a Swedish Parkinson case-control material consisting of 241 patients and 307 neurologically healthy controls. </plain></SENT>
<SENT sid="4" pm="."><plain>None of the analyzed polymorphisms in MIRO1 and MIRO2 were significantly associated with PD. </plain></SENT>
<SENT sid="5" pm="."><plain>Although we did not find a significant association with PD in our Swedish case-control material, we cannot exclude these Rho GTPases as candidate genes for PD or other neurodegenerative disorders. </plain></SENT>
</text></SecTag></p></abstract><SecTag type="KEYWORD"><kwd-group><title>Keywords</title><kwd>Association</kwd><kwd>mitochondria</kwd><kwd>single nucleotide polymorphism.</kwd></kwd-group></SecTag></article-meta></front><body><SecTag type="INTRO"><sec><label>1</label><title><text><SENT sid="6" pm="."><plain>INTRODUCTION </plain></SENT>
</text></title><p><text><SENT sid="7" pm="."><plain>Degeneration of dopamine (DA) neurons in substantia nigra (SN) pars compacta causes the typical motor symptoms seen in patients with Parkinson’s disease (PD); resting tremor, rigidity, bradykinesia and postural instability [1,2]. </plain></SENT>
<SENT sid="8" pm="."><plain>However, neuropathology in PD is widespread, affecting neurons in areas from the gastrointestinal tract to cerebral cortex [3]. </plain></SENT>
<SENT sid="9" pm="."><plain>In accordance with the systemic nature of the disease, there is increasing evidence that mitochondrial dysfunction may underlie some forms of PD [4-6]. </plain></SENT>
<SENT sid="10" pm="."><plain>Mitochondria are essential in all eukaryotic cells for generating ATP, calcium buffering and involvement in programmed cell death [7-9]. </plain></SENT>
<SENT sid="11" pm="."><plain>To adapt to cellular demands mitochondria undergo fusion and fission, two opposing processes that exist in equilibrium [10]. </plain></SENT>
<SENT sid="12" pm="."><plain>The mitochondrial network is very dynamic in neurons [11,12] and the rate of mitochondrial fusion and fission is high [13]. </plain></SENT>
<SENT sid="13" pm="."><plain>Recruitment of mitochondria to specific neuronal compartments has been shown to be an active ATP consuming process [14]. </plain></SENT>
<SENT sid="14" pm="."><plain>In support of a mitochondrial involvement in PD, the metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), which is 1-methyl-4-phenylpyridinium (MPP+), is a neurotoxin and inhibits the mitochondrial respiratory chain complex I, which causes degeneration of DA neurons in SN [15]. </plain></SENT>
<SENT sid="15" pm="."><plain>Another inhibitor of complex I is the pesticide rotenone. </plain></SENT>
<SENT sid="16" pm="."><plain>In rodents it causes selective degeneration of DA neurons, as well as other neurons to a lesser extent, thereby resembling the pathology of PD [16]. </plain></SENT>
<SENT sid="17" pm="."><plain>Complex I activity has been found to be reduced in SN and in platelets from PD patients [17]. </plain></SENT>
</text></p><p><text><SENT sid="18" pm="."><plain>Different polymorphisms in mtDNA have been reported to be associated with both increased and decreased risk of PD [18]. </plain></SENT>
<SENT sid="19" pm="."><plain>We and others have found associations between PD risk and two nuclear genes involved in mitochondrial maintenance, MTIF3 (mitochondrial translation initiation factor 3) and POLG1 (DNA polymerase gamma 1). MTIF3 is part of the initiation complex formation on the mitochondrial 55S ribosome and regulates translation of proteins within mitochondria [19,20]. </plain></SENT>
<SENT sid="20" pm="."><plain>A synonymous single nucleotide polymorphism (SNP) in MTIF3, rs7669, has been reported to be associated with PD in cohorts with different geographical origin [21-23]. POLG1 is important for replication and repair of the mitochondrial genome [24]. </plain></SENT>
<SENT sid="21" pm="."><plain>Variations in length of the polyglutamine tract of POLG1 have been found to associate with PD by a number of groups in different geographical regions [25-27]. </plain></SENT>
</text></p><p><text><SENT sid="22" pm="."><plain>Several of the PARK genes identified by linkage studies have been reported to influence mitochondria in different ways. </plain></SENT>
<SENT sid="23" pm="."><plain>Mutations in PTEN induced putative kinase 1 (PINK1) at PARK6, reported to regulate mitochondrial fission, cause early-onset familial PD [28]. </plain></SENT>
<SENT sid="24" pm="."><plain>Mutations in Parkin at PARK2 have been reported to cause autosomal recessive early-onset Parkinsonism [29]. </plain></SENT>
<SENT sid="25" pm="."><plain>Parkin acts in a similar way as PINK1 [30] and is believed to be recruited from the cytoplasm by PINK1 to initiate autophagic degradation of impaired mitochondria [31]. DJ-1 at PARK7 causes autosomal recessive early-onset Parkinsonism [32] and is suggested to operate in a parallel pathway to that of PINK1/Parkin to maintain mitochondrial function in oxidative environments [33]. </plain></SENT>
<SENT sid="26" pm="."><plain>Pink1 has been shown to be part of a mitochondrial multi-protein complex together with the atypical GTPases Miro1 and Miro2 (mitochondrial Ras homolog gene family, member T1 and T2) and the adaptor protein Milton [34]. </plain></SENT>
<SENT sid="27" pm="."><plain>This suggests that Pink1 also plays a role in mitochondrial trafficking. </plain></SENT>
</text></p><p><text><SENT sid="28" pm="."><plain>Miro1 and Miro2, also referred to as Rhot1 and Rhot2, belong to the mitochondrial Rho GTPase family and are involved in axonal transport of mitochondria [35,36]. </plain></SENT>
<SENT sid="29" pm="."><plain>Miro1 and Miro2 were first identified in yeast [37] and later described to share similarities with Rho GTPases [38]. </plain></SENT>
<SENT sid="30" pm="."><plain>Miro proteins have a C-terminal domain locating them to the mitochondrial outer membrane, as well as two GTPase domains and two calcium binding EF-hands [36,37]. </plain></SENT>
<SENT sid="31" pm="."><plain>Calcium binding to the EF-hands regulates the trafficking of mitochondria along microtubules [39,40]. </plain></SENT>
</text></p><p><text><SENT sid="32" pm="."><plain>Based on the finding that mitochondrial dysfunction has been implicated in PD [4,41], the importance of Miro1 and Miro2 in mitochondrial transport [35,36] and the link between Miro and Pink1 [34], we analyzed SNPs in MIRO1 and MIRO2 with regard to PD. </plain></SENT>
<SENT sid="33" pm="."><plain>We hypothesized that genetic variations in functionally important regions of these two genes might lead to disturbed mitochondrial trafficking, fusion and/or fission disturbances in neurons and hence increase the risk of neurodegenerative events, such as those observed in PD. </plain></SENT>
<SENT sid="34" pm="."><plain>We therefore investigated the possible association of five SNPs located in functional regions of the proteins MIRO1 and MIRO2. </plain></SENT>
<SENT sid="35" pm="."><plain>The SNPs were selected from the NCBI database and screened in a Swedish Parkinson case-control material (see Table 1). </plain></SENT>
<SENT sid="36" pm="."><plain>Three SNPs were selected in MIRO1, one synonymous SNP in the GTPase domain (rs16967164) and two non-synonymous SNPs in each of the two EF-hands (rs28630420, rs34538349). </plain></SENT>
<SENT sid="37" pm="."><plain>The other two SNPs were non-synonymous SNPs located in one of the EF-hand domains of MIRO2 (rs1139897 and rs3743912). </plain></SENT>
</text></p></sec></SecTag><SecTag type="METHODS"><sec><label>2</label><title><text><SENT sid="38" pm="."><plain>MATERIALS AND METHODOLOGY </plain></SENT>
</text></title><sec><label>2.1</label><title><text><SENT sid="39" pm="."><plain>Subjects </plain></SENT>
</text></title><p><text><SENT sid="40" pm="."><plain>A Swedish PD case-control material of Caucasian origin was genotyped for three SNPs in MIRO1 and two in MIRO2 (see Table 1). </plain></SENT>
<SENT sid="41" pm="."><plain>The PD material consisted of 241 individuals from the Stockholm area (mean age 67.0 years, 60.9% men). </plain></SENT>
<SENT sid="42" pm="."><plain>The DNA was obtained after informed oral and written consent and approval of the local ethics committee, Regionala etikprövningsnämnden, Stockholm, Sweden. </plain></SENT>
<SENT sid="43" pm="."><plain>All PD subjects met the United Kingdom Parkinson's Disease Society Brain Bank Criteria for PD except that more than one affected first, second or third degree relative was allowed [42]. </plain></SENT>
<SENT sid="44" pm="."><plain>Control subjects consisted of 307 neurologically healthy spouses of PD patients and individuals from the SNAC-K project (The Swedish National Study on Aging and Care in Kungsholmen) from the Stockholm area (mean age 64.2 years, 40.4% men). </plain></SENT>
<SENT sid="45" pm="."><plain>DNA was extracted from blood according to standard protocols. </plain></SENT>
</text></p></sec><sec><label>2.2</label><title><text><SENT sid="46" pm="."><plain>Genotyping </plain></SENT>
</text></title><p><text><SENT sid="47" pm="."><plain>The SNPs were genotyped with predesigned TaqMan SNP Genotyping Assays: C_1630552_10 (rs16967164), C_60583023_10 (rs28630420), C_25937296_10 (rs3743912), C_2463996_1_ (rs1139897) and a custom designed assay (rs34538349) using a fast real-time PCR instrument (ABI 7500 FAST Real-Time PCR, Applied Biosystems, Foster City, CA, USA). </plain></SENT>
<SENT sid="48" pm="."><plain>The TaqMan assay contained primers and 5´ fluorescently labeled (FAM and VIC) minor groove binding probes (20×) for detection of the SNPs. </plain></SENT>
<SENT sid="49" pm="."><plain>Allelic discrimination was run with pre- and custom-designed primers and probes, genotyping master mix (TaqMan®, Applied Biosystems, Foster City, CA, USA) and 10-20 ng of genomic DNA in a total reaction volume of 10 µl mixed in transparent 96-well plates. </plain></SENT>
<SENT sid="50" pm="."><plain>The polymerase chain reaction (PCR) conditions followed the recommendations of default settings for the SNP assay, except that the number of cycles were set to 55 and run at 92°C for 15 s. </plain></SENT>
<SENT sid="51" pm="."><plain>The ramp speed was set to standard. </plain></SENT>
<SENT sid="52" pm="."><plain>A post-PCR read was done for allelic discrimination using appropriate software (SDS version 2.0.4) supplied with the instrument. </plain></SENT>
<SENT sid="53" pm="."><plain>To test for genotyping errors we used water as negative controls and re-genotyped randomly chosen samples to confirm the results. </plain></SENT>
<SENT sid="54" pm="."><plain>Case-control analysis between individual sequence variants in MIRO1 and MIRO2 were performed using a Chi-square (χ2) test [43]. </plain></SENT>
<SENT sid="55" pm="."><plain>Three PD patients previously known to carry the pathogenic G2019S mutation in leucine-rich repeat kinase 2 (LRRK2) were excluded from the association analysis. </plain></SENT>
<SENT sid="56" pm="."><plain>Distribution of genotypes in controls was tested for consistency with the Hardy-Weinberg equilibrium. </plain></SENT>
<SENT sid="57" pm="."><plain>Statistical significance was defined as p&lt; 0.05. </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="RESULTS"><sec><label>3</label><title><text><SENT sid="58" pm="."><plain>RESULTS </plain></SENT>
</text></title><p><text><SENT sid="59" pm="."><plain>The results from the TaqMan genotyping of the five SNPs in MIRO1 and MIRO2 are presented in Table 2. </plain></SENT>
<SENT sid="60" pm="."><plain>We did not find any genotypic or allelic (data available upon request) association of the MIRO1 or MIRO2 SNPs screened in our Swedish Parkinson case-control material. </plain></SENT>
<SENT sid="61" pm="."><plain>The observed frequencies of the controls were in agreement with the Hardy-Weinberg equilibrium (data not shown). </plain></SENT>
<SENT sid="62" pm="."><plain>For two of the SNPs in MIRO1 (rs28630420, rs34538349) we only observed the wild-type genotype. </plain></SENT>
</text></p><p><text><SENT sid="63" pm="."><plain>To investigate if any of the SNPs had a possible effect on age of onset we stratified the material into early disease onset (≤50 years) or late disease onset (&gt;50 years) and compared genotype and allele frequencies. </plain></SENT>
<SENT sid="64" pm="."><plain>However, such stratification did not reveal any significant associations with disease at genotype or allele (data available upon request) levels, as shown in Table 3. </plain></SENT>
</text></p></sec></SecTag><SecTag type="DISCUSS"><sec><label>4</label><title><text><SENT sid="65" pm="."><plain>DISCUSSION </plain></SENT>
</text></title><p><text><SENT sid="66" pm="."><plain>Dysfunctional mitochondria may be the cause or the consequence of DA neuron degeneration in PD. </plain></SENT>
<SENT sid="67" pm="."><plain>This is the first genetic study analyzing possible links between the two GTPases MIRO1 and MIRO2 and disease in general and neurodegenerative disease in particular. </plain></SENT>
<SENT sid="68" pm="."><plain>Two functionally important regions in the two Miro proteins are the two GTPase domains and two calcium binding EF-hands [36,37]. </plain></SENT>
<SENT sid="69" pm="."><plain>Another protein with a GTPase domain linked to PD is leucine-rich repeat kinase 2 (LRRK2), a large protein with multiple domains, including functional Roc GTPase and a protein kinase domain. </plain></SENT>
<SENT sid="70" pm="."><plain>Several mutations in the kinase domain of LRRK2 are associated with both sporadic and familial PD [44]. </plain></SENT>
<SENT sid="71" pm="."><plain>Recently, a new mutation (N1437S) localized within the GTPase domain of LRRK2 (PARK8) was found to cosegregate with PD [45]. </plain></SENT>
<SENT sid="72" pm="."><plain>Furthermore, it has been suggested that the GTPase domain may contribute to the toxicity of LRRK2 [46]. </plain></SENT>
<SENT sid="73" pm="."><plain>Interestingly, knockdown of lrk-1, the ortholog of LRRK2 in C. elegans, has been reported to lead to reduced survival and is associated with dysfunctional mitochondria [47]. </plain></SENT>
<SENT sid="74" pm="."><plain>There are no reports on proteins with EF-hand domains being linked to PD today. </plain></SENT>
</text></p><p><text><SENT sid="75" pm="."><plain>It has been shown that all domains of Gem1P (i.e. yeast Miro) are needed for proper mitochondrial morphology [37]. </plain></SENT>
<SENT sid="76" pm="."><plain>Loss-of-function mutations in the Miro GTPase in Drosophila melanogaster lead to impaired locomotion and premature death of the flies [48]. </plain></SENT>
<SENT sid="77" pm="."><plain>Based on these findings we selected polymorphisms that are located in functional regions in MIRO1 and MIRO2 to analyze possible association with risk for neurodegeneration. </plain></SENT>
<SENT sid="78" pm="."><plain>The three selected MIRO1 SNPs are localized in one of the GTPase domains (rs16967164) and in each of the two EF-hands (rs28630420, rs34538349). </plain></SENT>
<SENT sid="79" pm="."><plain>The two SNPs in MIRO2 (rs1139897 and rs3743912) are situated in one of the EF-hand domains. </plain></SENT>
<SENT sid="80" pm="."><plain>We did not find association with any of the selected SNPs in our Swedish case-control material. </plain></SENT>
<SENT sid="81" pm="."><plain>For two of the SNPs in MIRO1 (rs28630420 and rs34538349) we only detected the wild-type genotype in our material of cases and controls. </plain></SENT>
<SENT sid="82" pm="."><plain>Thus these two mutations tend to be very rare in the area from which our DNA samples have been collected. </plain></SENT>
<SENT sid="83" pm="."><plain>The results after stratification of the material regarding age of onset did not reveal any age-of-onset association with any of the detected polymorphisms. </plain></SENT>
<SENT sid="84" pm="."><plain>Further genetic analysis and functional studies in disease are however needed before one can exclude MIRO1 and MIRO2 as potential candidate genes for PD. </plain></SENT>
</text></p></sec></SecTag><SecTag type="CONCL"><sec><title><text><SENT sid="85" pm="."><plain>CONCLUSION </plain></SENT>
</text></title><p><text><SENT sid="86" pm="."><plain>Genetic variation in MIRO1 and MIRO2 might influence transport of mitochondria along microtubules, leading to reduced local energy production which can lead to degeneration of DA neurons. </plain></SENT>
<SENT sid="87" pm="."><plain>Although we did not find a significant association with PD and the selected polymorphisms in MIRO1 and MIRO2 in our Swedish case-control material, we cannot exclude these Rho GTPases as candidate genes for PD or other neurodegenerative disorders. </plain></SENT>
</text></p></sec></SecTag></body><back><SecTag type="ACK_FUND"><ack><title>ACKNOWLEDGEMENT</title><p><text4fund><text><SENT sid="88" pm="."><plain>We would like to thank Professor Laura Fratiglioni for providing us with control samples from the Swedish National Study on Aging and Care in Kungsholmen (SNAC-K) project and Doctor Fengqing Xiang for excellent technical assistance. </plain></SENT>
<SENT sid="89" pm="."><plain>The study was supported by the Swedish Research Council, the Swedish Brain Foundation, Karolinska Institutet Funds, Magnus Bergvalls stiftelse, the Swedish Parkinson Foundation, Åke Wibergs stiftelse and Swedish Brain Power. </plain></SENT>
</text></text4fund></p></ack></SecTag><SecTag type="COMP_INT"><sec><title>CONFLICT OF INTEREST</title><p>None declared.</p></sec></SecTag><SecTag type="REF"><ref-list><title>REFERENCES</title><ref id="R1"><text><SENT sid="90" pm="."><plain>1 KovariEHorvathJBourasCNeuropathology of Lewy body disordersBrain Res Bull2009802031019576266 </plain></SENT>
</text></ref><ref id="R2"><text><SENT sid="91" pm="."><plain>2 LeesAJHardyJReveszTParkinson's diseaseLancet200937320556619524782 </plain></SENT>
</text></ref><ref id="R3"><text><SENT sid="92" pm="."><plain>3 BraakHde VosRABohlJDelTKGastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathologyNeurosci Lett2006396677216330147 </plain></SENT>
</text></ref><ref id="R4"><text><SENT sid="93" pm="."><plain>4 LinMTBealMFMitochondrial dysfunction and oxidative stress in neurodegenerative diseasesNature20064437879517051205 </plain></SENT>
</text></ref><ref id="R5"><text><SENT sid="94" pm="."><plain>5 SchapiraAHMitochondria in the aetiology and pathogenesis of Parkinson's diseaseLancet Neurol200879710918093566 </plain></SENT>
</text></ref><ref id="R6"><text><SENT sid="95" pm="."><plain>6 VilaMRamonetDPerierCMitochondrial alterations in Parkinson's disease: new cluesJ Neurochem20081073172818680555 </plain></SENT>
</text></ref><ref id="R7"><text><SENT sid="96" pm="."><plain>7 BernardiPPetronilliVDiLFForteMA mitochondrial perspective on cell deathTrends Biochem Sci200126112711166569 </plain></SENT>
</text></ref><ref id="R8"><text><SENT sid="97" pm="."><plain>8 ChanDCMitochondria: dynamic organelles in disease, aging, and developmentCell200612512415216814712 </plain></SENT>
</text></ref><ref id="R9"><text><SENT sid="98" pm="."><plain>9 DavidGBarrettEFStimulation-evoked increases in cytosolic [Ca(2+)] in mouse motor nerve terminals are limited by mitochondrial uptake and are temperature-dependentJ Neurosci2000207290611007886 </plain></SENT>
</text></ref><ref id="R10"><text><SENT sid="99" pm="."><plain>10 Bereiter-HahnJVothMDynamics of mitochondria in living cells: shape changes, dislocations, fusion, and fission of mitochondriaMicrosc Res Tech1994271982198204911 </plain></SENT>
</text></ref><ref id="R11"><text><SENT sid="100" pm="."><plain>11 ChenHChanDCCritical dependence of neurons on mitochondrial dynamicsCurr Opin Cell Biol200618453916781135 </plain></SENT>
</text></ref><ref id="R12"><text><SENT sid="101" pm="."><plain>12 HollenbeckPJSaxtonWMThe axonal transport of mitochondriaJ Cell Sci20051185411916306220 </plain></SENT>
</text></ref><ref id="R13"><text><SENT sid="102" pm="."><plain>13 KuznetsovAVHermannMSaksVHengsterPMargreiterRThe cell-type specificity of mitochondrial dynamicsInt J Biochem Cell Biol20094119283919703655 </plain></SENT>
</text></ref><ref id="R14"><text><SENT sid="103" pm="."><plain>14 ChangDTHonickASReynoldsIJMitochondrial trafficking to synapses in cultured primary cortical neuronsJ Neurosci20062670354516807333 </plain></SENT>
</text></ref><ref id="R15"><text><SENT sid="104" pm="."><plain>15 LangstonJWBallardPTetrudJWIrwinIChronic Parkinsonism in humans due to a product of meperidine-analog synthesisScience1983219979806823561 </plain></SENT>
</text></ref><ref id="R16"><text><SENT sid="105" pm="."><plain>16 GreenamyreJTMacKenzieGPengTIStephansSEMitochondrial dysfunction in Parkinson's diseaseBiochem Soc Symp199966859710989660 </plain></SENT>
</text></ref><ref id="R17"><text><SENT sid="106" pm="."><plain>17 van der WaltJMNicodemusKKMartinERMitochondrial polymorphisms significantly reduce the risk of Parkinson diseaseAm J Hum Genet2003728041112618962 </plain></SENT>
</text></ref><ref id="R18"><text><SENT sid="107" pm="."><plain>18 OtaeguiDPaisanCSaenzAMitochondrial polymporphisms in Parkinson's DiseaseNeurosci Lett2004370171415488317 </plain></SENT>
</text></ref><ref id="R19"><text><SENT sid="108" pm="."><plain>19 ChristianBESpremulliLLEvidence for an active role of IF3mt in the initiation of translation in mammalian mitochondriaBiochemistry20094832697819239245 </plain></SENT>
</text></ref><ref id="R20"><text><SENT sid="109" pm="."><plain>20 KocECSpremulliLLIdentification of mammalian mitochondrial translational initiation factor 3 and examination of its role in initiation complex formation with natural mRNAsJ Biol Chem200227735541912095986 </plain></SENT>
</text></ref><ref id="R21"><text><SENT sid="110" pm="."><plain>21 AbahuniNGispertSBauerPMitochondrial translation initiation factor 3 gene polymorphism associated with Parkinson's diseaseNeurosci Lett2007414126917267121 </plain></SENT>
</text></ref><ref id="R22"><text><SENT sid="111" pm="."><plain>22 AnvretARanCWesterlundMPossible involvement of a mitochondrial translation initiation factor 3 variant causing decreased mRNA levels in Parkinson's diseaseParkinsons Dis2010201049175120976088 </plain></SENT>
</text></ref><ref id="R23"><text><SENT sid="112" pm="."><plain>23 BehrouzBVilarino-GuellCHeckmanMGMitochondrial translation initiation factor 3 polymorphism and Parkinson's diseaseNeurosci Lett20104862283020887776 </plain></SENT>
</text></ref><ref id="R24"><text><SENT sid="113" pm="."><plain>24 KaguniLSDNA polymerase gamma, the mitochondrial replicaseAnnu Rev Biochem20047329332015189144 </plain></SENT>
</text></ref><ref id="R25"><text><SENT sid="114" pm="."><plain>25 AnvretAWesterlundMSydowOVariations of the CAG trinucleotide repeat in DNA polymerase gamma (POLG1) is associated with Parkinson's disease in SwedenNeurosci Lett20104851172020826197 </plain></SENT>
</text></ref><ref id="R26"><text><SENT sid="115" pm="."><plain>26 EerolaJLuomaPTPeuralinnaTPOLG1 polyglutamine tract variants associated with Parkinson's diseaseNeurosci Lett2010 </plain></SENT>
</text></ref><ref id="R27"><text><SENT sid="116" pm="."><plain>27 LuomaPTEerolaJAholaSMitochondrial DNA polymerase gamma variants in idiopathic sporadic Parkinson diseaseNeurology2007691152917846414 </plain></SENT>
</text></ref><ref id="R28"><text><SENT sid="117" pm="."><plain>28 ValenteEMAbou-SleimanPMCaputoVHereditary early-onset Parkinson's disease caused by mutations in PINK1Science200430411586015087508 </plain></SENT>
</text></ref><ref id="R29"><text><SENT sid="118" pm="."><plain>29 KitadaTAsakawaSHattoriNMutations in the parkin gene cause autosomal recessive juvenile parkinsonismNature199839260589560156 </plain></SENT>
</text></ref><ref id="R30"><text><SENT sid="119" pm="."><plain>30 PooleACThomasREAndrewsLAThe PINK1/Parkin pathway regulates mitochondrial morphologyProc Natl Acad Sci U S A200810516384318230723 </plain></SENT>
</text></ref><ref id="R31"><text><SENT sid="120" pm="."><plain>31 MatsudaNSatoSShibaKPINK1 stabilized by mitochondrial depolarization recruits Parkin to damaged mitochondria and activates latent Parkin for mitophagyJ Cell Biol20101892112120404107 </plain></SENT>
</text></ref><ref id="R32"><text><SENT sid="121" pm="."><plain>32 van DuijnCMDekkerMCBonifatiVPark7, a novel locus for autosomal recessive early-onset parkinsonism, on chromosome 1p36Am J Hum Genet2001696293411462174 </plain></SENT>
</text></ref><ref id="R33"><text><SENT sid="122" pm="."><plain>33 ThomasKJMcCoyMKBlackintonJDJ-1 acts in parallel to the PINK1/parkin pathway to control mitochondrial function and autophagyHum Mol Genet2010201405020940149 </plain></SENT>
</text></ref><ref id="R34"><text><SENT sid="123" pm="."><plain>34 WeihofenAThomasKJOstaszewskiBCooksonMSelkoeDJPink1 forms a multi-protein complex with Miro and Milton, linking Pink1 function to mitochondrial traffickingBiochemistry2009 </plain></SENT>
</text></ref><ref id="R35"><text><SENT sid="124" pm="."><plain>35 MacaskillAFBrickleyKStephensonFAKittlerJTGTPase dependent recruitment of Grif-1 by Miro1 regulates mitochondrial trafficking in hippocampal neuronsMol Cell Neurosci20094033011219103291 </plain></SENT>
</text></ref><ref id="R36"><text><SENT sid="125" pm="."><plain>36 FranssonSRuusalaAAspenstromPThe atypical Rho GTPases Miro-1 and Miro-2 have essential roles in mitochondrial traffickingBiochem Biophys Res Commun20063445001016630562 </plain></SENT>
</text></ref><ref id="R37"><text><SENT sid="126" pm="."><plain>37 FrederickRLMcCafferyJMCunninghamKWOkamotoKShawJMYeast Miro GTPase, Gem1p, regulates mitochondrial morphology via a novel pathwayJ Cell Biol2004167879815479738 </plain></SENT>
</text></ref><ref id="R38"><text><SENT sid="127" pm="."><plain>38 FranssonARuusalaAAspenstromPAtypical Rho GTPases have roles in mitochondrial homeostasis and apoptosisJ Biol Chem2003278649550212482879 </plain></SENT>
</text></ref><ref id="R39"><text><SENT sid="128" pm="."><plain>39 Lewit-BentleyARetySEF-hand calcium-binding proteinsCurr Opin Struct Biol2000106374311114499 </plain></SENT>
</text></ref><ref id="R40"><text><SENT sid="129" pm="."><plain>40 MacaskillAFRinholmJETwelvetreesAEMiro1 is a calcium sensor for glutamate receptor-dependent localization of mitochondria at synapsesNeuron2009615415519249275 </plain></SENT>
</text></ref><ref id="R41"><text><SENT sid="130" pm="."><plain>41 BaronMKudinAPKunzWSMitochondrial dysfunction in neurodegenerative disordersBiochem Soc Trans20073512283117956319 </plain></SENT>
</text></ref><ref id="R42"><text><SENT sid="131" pm="."><plain>42 DanielSELeesAJParkinson's Disease Society Brain Bank, London: overview and researchJ Neural Transm Suppl199339165728360656 </plain></SENT>
</text></ref><ref id="R43"><text><SENT sid="132" pm="."><plain>43 ShamPCCurtisDMonte Carlo tests for associations between disease and alleles at highly polymorphic lociAnn Hum Genet199559971057762987 </plain></SENT>
</text></ref><ref id="R44"><text><SENT sid="133" pm="."><plain>44 BelinACWesterlundMParkinson's disease: a genetic perspectiveFEBS J200827513778318279377 </plain></SENT>
</text></ref><ref id="R45"><text><SENT sid="134" pm="."><plain>45 AaslyJOVilarino-GuellCDachselJCNovel pathogenic LRRK2 p.Asn1437His substitution in familial Parkinson's diseaseMov Disord20102521566320669305 </plain></SENT>
</text></ref><ref id="R46"><text><SENT sid="135" pm="."><plain>46 XiongYCoombesCEKilaruAGTPase activity plays a key role in the pathobiology of LRRK2PLoS Genet20106e100090220386743 </plain></SENT>
</text></ref><ref id="R47"><text><SENT sid="136" pm="."><plain>47 SahaSGuillilyMDFerreeALRRK2 modulates vulnerability to mitochondrial dysfunction in Caenorhabditis elegansJ Neurosci2009299210819625511 </plain></SENT>
</text></ref><ref id="R48"><text><SENT sid="137" pm="."><plain>48 GuoXMacleodGTWellingtonAThe GTPase dMiro is required for axonal transport of mitochondria to Drosophila synapsesNeuron2005473799316055062 </plain></SENT>
</text></ref></ref-list></SecTag></back><floats-group><SecTag type="TABLE"><table-wrap id="T1" position="float"><label>Table 1.</label><caption><p><text><SENT sid="138" pm="."><plain>Investigated Polymorphisms in MIRO1 and MIRO2, their Nucleotide Position, Consequence, Genomic Location and Functional Protein Region </plain></SENT>
</text></p></caption></table-wrap></SecTag><SecTag type="TABLE"><table-wrap id="T2" position="float"><label>Table 2.</label><caption><p><text><SENT sid="139" pm="."><plain>Genotype Frequencies of MIRO1 and MIRO2 Variants in Swedish Patients with Parkinson´s Disease (PD) Compared to Matched Neurologically Healthy Controls Analyzed using a Two-sided Chi-square (χ2) test </plain></SENT>
</text></p></caption></table-wrap></SecTag><SecTag type="TABLE"><table-wrap id="T3" position="float"><label>Table 3.</label><caption><p><text><SENT sid="140" pm="."><plain>Stratification of Parkinson’s Disease (PD) Cases into Early (≤50 years) and Late Onset (&gt;50 years), Comparing MIRO1 and MIRO2 Genotype Frequencies Analyzed using a Two-sided Chi-square (χ2) Test </plain></SENT>
</text></p></caption></table-wrap></SecTag></floats-group></article>
